Morgan Noble

Mindoula Health, Inc. is a mental health care and behavioral health management company based in Silver Spring, Maryland. Founded in 2013, it operates across multiple states, including Maryland, Virginia, and California. Mindoula's technology-enabled platform is designed to identify, engage, and support individuals facing complex behavioral health, medical, and social challenges throughout their care journey. By employing an adaptive data science approach and a multi-platform technology stack, Mindoula integrates behavioral, medical, and social determinants of health to improve patient outcomes and reduce costs for its payer and provider partners. The company offers a continuum of care through virtual and in-person services, catering to both individuals and families with direct-consumer subscription options.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

TARA Biosystems, Inc. is a biotechnology company focused on developing organ-on-a-chip technology, specifically human cardiac tissue models, to enhance drug discovery and safety assessments. Founded in 2014 and based in the United States, the company utilizes stem cell-derived cardiac tissue that mimics adult physiological conditions, enabling precise measurement of cardiac functionality. This innovative platform aims to facilitate the faster and safer development of new therapies by providing predictive in vitro models that can assess the effects of drug compounds on heart function without the need for human testing. Through its advanced technology, TARA Biosystems seeks to improve the health of patients by enabling more reliable assessments of cardiac drug efficacy and safety.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Mindoula Health, Inc. is a mental health care and behavioral health management company based in Silver Spring, Maryland. Founded in 2013, it operates across multiple states, including Maryland, Virginia, and California. Mindoula's technology-enabled platform is designed to identify, engage, and support individuals facing complex behavioral health, medical, and social challenges throughout their care journey. By employing an adaptive data science approach and a multi-platform technology stack, Mindoula integrates behavioral, medical, and social determinants of health to improve patient outcomes and reduce costs for its payer and provider partners. The company offers a continuum of care through virtual and in-person services, catering to both individuals and families with direct-consumer subscription options.

Privia Health, LLC is a physician practice management and population health technology company based in Arlington, Virginia, founded in 2007. The company partners with medical groups, health plans, and health systems to enhance physician practices and improve patient experiences. Privia Health offers a cloud-based technology platform designed to optimize healthcare delivery and promote patient engagement. Its services include a high-performance physician group, an accountable care organization, and population health management programs, all aimed at aligning reimbursements with quality outcomes. By focusing on both in-person and virtual care settings, Privia Health seeks to reduce unnecessary healthcare costs and improve patient health and provider well-being. The company maintains strategic alliances with organizations such as Premier Medical Group and Children’s Health, emphasizing its commitment to fostering a healthier patient population through innovative solutions.